nCounter® Elements™ General Purpose Reagents Expand the Company's Growing Portfolio of Solutions for Laboratories to Develop Tests for Personalized Medicine
Using nCounter Elements laboratories can independently design and
develop custom assays for gene expression, copy number variation, or
gene fusions for up to 216 custom targets of interest in a single tube.
The nCounter Elements reagents have been listed with the
The commercial launch was preceded by a successful early access program
that included 22 participants from the U.S.,
"The nCounter Elements chemistry provides a path for laboratories to
rapidly translate biomarkers and gene signature discoveries into
clinically useful tools," said
"The success of the Elements early access program further demonstrates
that the nCounter Analysis System is the ideal platform to advance
disease research, validate discoveries, and translate them into
clinically useful molecular testing assays," said
For more information on nCounter Elements, please visit www.nanostring.com/nCounterElements.
For more information, please visit www.nanostring.com.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements regarding the expected capabilities of nCounter
Elements and the use of nCounter Elements to develop clinical assays.
Forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially and reported results
should not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: risks
associated with keeping pace with rapidly changing technology and
customer requirements; risks regarding the company's ability to
successfully introduce new products; risks that new market opportunities
may not develop as quickly as expected; risks associated with
competition in marketing and selling products; risks of increased
regulatory requirements; as well as the other risks set forth in the
company's filings with the
News Provided by Acquire Media